These findings provide new insights for the potential clinical use of PPAR-γ agonists as anticancer agents especially in tumors characterized by IGFs’ overactivation and/or occurring in patients with insulin resistance and hyperinsulinemia. The gene discussed is PPARG; the disease is Insulin resistance.